{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:55:47Z","timestamp":1791618947593,"version":"4.3.4"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2002,3,12]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>\n                <jats:bold>\n                  <jats:italic>Background<\/jats:italic>\n                <\/jats:bold>\n                \u2014\n              <\/jats:italic>\n            <\/jats:bold>\n            The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial showed that pravastatin significantly reduced mortality and coronary heart disease (CHD) events in 9014 patients with known CHD and total cholesterol 4.0 to 7.0 mmol\/L at baseline. Secondary objectives included assessment of CHD event reduction according to lipid levels.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>\n                <jats:bold>\n                  <jats:italic>Methods and Results<\/jats:italic>\n                <\/jats:bold>\n                \u2014\n              <\/jats:italic>\n            <\/jats:bold>\n            We investigated the relationships of baseline and on-study lipids with subsequent CHD events in separate Cox models. Treatment effect on CHD event reduction was examined by baseline lipids and after adjustment for on-study lipid levels. Baseline lipids were significant predictors of CHD events. The adjusted relative risk per mmol\/L (on placebo) was 1.24 (\n            <jats:italic>P<\/jats:italic>\n            =0.004) for total cholesterol, 1.28 (\n            <jats:italic>P<\/jats:italic>\n            =0.002) for low-density lipoprotein cholesterol, and 0.52 (\n            <jats:italic>P<\/jats:italic>\n            =0.004) for high-density lipoprotein cholesterol. Apolipoproteins A1 and B were strong predictors (each\n            <jats:italic>P<\/jats:italic>\n            =0.001). Pravastatin reduced the risk of the composite outcome of fatal CHD or nonfatal myocardial infarction by 24% (95% confidence interval [CI], 15% to 32%) and the expanded end point of fatal CHD, nonfatal myocardial infarction, unstable angina, or coronary revascularization by 17% (95% CI, 10% to 24%). Similar relative effects were observed for different categories of baseline lipids. The proportion of treatment effect explained by on-study lipid levels was 67% (95% CI, 27% to 106%) for the composite and 97% (95% CI, 49% to 145%) for the expanded end point. The most important lipids associated with event reduction were apolipoprotein B, low-density lipoprotein cholesterol, and the combination of total and high-density lipoprotein cholesterol.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>\n                <jats:bold>\n                  <jats:italic>Conclusions<\/jats:italic>\n                <\/jats:bold>\n                \u2014\n              <\/jats:italic>\n            <\/jats:bold>\n            Changes in lipid levels can explain all or most of the observed benefit of pravastatin. Some treatment effect may also be mediated through nonlipid changes.\n          <\/jats:p>","DOI":"10.1161\/hc1002.105136","type":"journal-article","created":{"date-parts":[[2002,7,28]],"date-time":"2002-07-28T23:16:07Z","timestamp":1027898167000},"page":"1162-1169","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":194,"title":["Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial"],"prefix":"10.1161","volume":"105","author":[{"given":"R. John","family":"Simes","sequence":"first","affiliation":[{"name":"From the National Health and Medical Research Council Clinical Trials Centre (R.J.S., I.C.M., W.H, A.K.), University of Sydney, Sydney; Royal Melbourne Hospital (D.H.), Melbourne; University of Queensland (D.C.), Brisbane; Royal Prince Alfred Hospital (D.S.), Sydney; University of Otago (R.A.H.S.), Dunedin; Sir Charles Gairdner Hospital (P.T.), Perth; Green Lane Hospital (H.W.), Auckland; and National Heart Foundation (J.S., A.T.), Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C.","family":"Marschner","sequence":"additional","affiliation":[{"name":"From the National Health and Medical Research Council Clinical Trials Centre (R.J.S., I.C.M., W.H, A.K.), University of Sydney, Sydney; Royal Melbourne Hospital (D.H.), Melbourne; University of Queensland (D.C.), Brisbane; Royal Prince Alfred Hospital (D.S.), Sydney; University of Otago (R.A.H.S.), Dunedin; Sir Charles Gairdner Hospital (P.T.), Perth; Green Lane Hospital (H.W.), Auckland; and National Heart Foundation (J.S., A.T.), Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hunt","sequence":"additional","affiliation":[{"name":"From the National Health and Medical Research Council Clinical Trials Centre (R.J.S., I.C.M., W.H, A.K.), University of Sydney, Sydney; Royal Melbourne Hospital (D.H.), Melbourne; University of Queensland (D.C.), Brisbane; Royal Prince Alfred Hospital (D.S.), Sydney; University of Otago (R.A.H.S.), Dunedin; Sir Charles Gairdner Hospital (P.T.), Perth; Green Lane Hospital (H.W.), Auckland; and National Heart Foundation (J.S., A.T.), Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Colquhoun","sequence":"additional","affiliation":[{"name":"From the National Health and Medical Research Council Clinical Trials Centre (R.J.S., I.C.M., W.H, A.K.), University of Sydney, Sydney; Royal Melbourne Hospital (D.H.), Melbourne; University of Queensland (D.C.), Brisbane; Royal Prince Alfred Hospital (D.S.), Sydney; University of Otago (R.A.H.S.), Dunedin; Sir Charles Gairdner Hospital (P.T.), Perth; Green Lane Hospital (H.W.), Auckland; and National Heart Foundation (J.S., A.T.), Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sullivan","sequence":"additional","affiliation":[{"name":"From the National Health and Medical Research Council Clinical Trials Centre (R.J.S., I.C.M., W.H, A.K.), University of Sydney, Sydney; Royal Melbourne Hospital (D.H.), Melbourne; University of Queensland (D.C.), Brisbane; Royal Prince Alfred Hospital (D.S.), Sydney; University of Otago (R.A.H.S.), Dunedin; Sir Charles Gairdner Hospital (P.T.), Perth; Green Lane Hospital (H.W.), Auckland; and National Heart Foundation (J.S., A.T.), Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.H.","family":"Stewart","sequence":"additional","affiliation":[{"name":"From the National Health and Medical Research Council Clinical Trials Centre (R.J.S., I.C.M., W.H, A.K.), University of Sydney, Sydney; Royal Melbourne Hospital (D.H.), Melbourne; University of Queensland (D.C.), Brisbane; Royal Prince Alfred Hospital (D.S.), Sydney; University of Otago (R.A.H.S.), Dunedin; Sir Charles Gairdner Hospital (P.T.), Perth; Green Lane Hospital (H.W.), Auckland; and National Heart Foundation (J.S., A.T.), Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Hague","sequence":"additional","affiliation":[{"name":"From the National Health and Medical Research Council Clinical Trials Centre (R.J.S., I.C.M., W.H, A.K.), University of Sydney, Sydney; Royal Melbourne Hospital (D.H.), Melbourne; University of Queensland (D.C.), Brisbane; Royal Prince Alfred Hospital (D.S.), Sydney; University of Otago (R.A.H.S.), Dunedin; Sir Charles Gairdner Hospital (P.T.), Perth; Green Lane Hospital (H.W.), Auckland; and National Heart Foundation (J.S., A.T.), Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Keech","sequence":"additional","affiliation":[{"name":"From the National Health and Medical Research Council Clinical Trials Centre (R.J.S., I.C.M., W.H, A.K.), University of Sydney, Sydney; Royal Melbourne Hospital (D.H.), Melbourne; University of Queensland (D.C.), Brisbane; Royal Prince Alfred Hospital (D.S.), Sydney; University of Otago (R.A.H.S.), Dunedin; Sir Charles Gairdner Hospital (P.T.), Perth; Green Lane Hospital (H.W.), Auckland; and National Heart Foundation (J.S., A.T.), Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Thompson","sequence":"additional","affiliation":[{"name":"From the National Health and Medical Research Council Clinical Trials Centre (R.J.S., I.C.M., W.H, A.K.), University of Sydney, Sydney; Royal Melbourne Hospital (D.H.), Melbourne; University of Queensland (D.C.), Brisbane; Royal Prince Alfred Hospital (D.S.), Sydney; University of Otago (R.A.H.S.), Dunedin; Sir Charles Gairdner Hospital (P.T.), Perth; Green Lane Hospital (H.W.), Auckland; and National Heart Foundation (J.S., A.T.), Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"White","sequence":"additional","affiliation":[{"name":"From the National Health and Medical Research Council Clinical Trials Centre (R.J.S., I.C.M., W.H, A.K.), University of Sydney, Sydney; Royal Melbourne Hospital (D.H.), Melbourne; University of Queensland (D.C.), Brisbane; Royal Prince Alfred Hospital (D.S.), Sydney; University of Otago (R.A.H.S.), Dunedin; Sir Charles Gairdner Hospital (P.T.), Perth; Green Lane Hospital (H.W.), Auckland; and National Heart Foundation (J.S., A.T.), Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Shaw","sequence":"additional","affiliation":[{"name":"From the National Health and Medical Research Council Clinical Trials Centre (R.J.S., I.C.M., W.H, A.K.), University of Sydney, Sydney; Royal Melbourne Hospital (D.H.), Melbourne; University of Queensland (D.C.), Brisbane; Royal Prince Alfred Hospital (D.S.), Sydney; University of Otago (R.A.H.S.), Dunedin; Sir Charles Gairdner Hospital (P.T.), Perth; Green Lane Hospital (H.W.), Auckland; and National Heart Foundation (J.S., A.T.), Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Tonkin","sequence":"additional","affiliation":[{"name":"From the National Health and Medical Research Council Clinical Trials Centre (R.J.S., I.C.M., W.H, A.K.), University of Sydney, Sydney; Royal Melbourne Hospital (D.H.), Melbourne; University of Queensland (D.C.), Brisbane; Royal Prince Alfred Hospital (D.S.), Sydney; University of Otago (R.A.H.S.), Dunedin; Sir Charles Gairdner Hospital (P.T.), Perth; Green Lane Hospital (H.W.), Auckland; and National Heart Foundation (J.S., A.T.), Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03380200061022"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199006143222403"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-9-687"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6925.367"},{"key":"e_1_3_2_5_2","first-page":"III-51.","volume":"72","year":"1985","unstructured":"Peto R, Yusuf S, Collins R. Cholesterol lowering trial results in their epidemiological context. Circulation. 1985; 72 (suppl III): III-51.","journal-title":"Circulation"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199010183231606"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811053391902"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","year":"1972","unstructured":"Cox DR. Regression methods of life tables (with discussion). J R Stat Soc. 1972; B34: 187\u2013220.","journal-title":"J R Stat Soc"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01360-2"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Carroll RJ Ruppert D Stefanski LA. Measurement Error in Nonlinear Models. New York: Chapman and Hall; 1995.","DOI":"10.1007\/978-1-4899-4477-1"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780110204"},{"key":"e_1_3_2_13_2","unstructured":"Law M. Lowering cardiovascular risk by cholesterol reduction: evidence from observational studies and randomized trials. In: Betteridge DJ ed. Lipids and Vascular Disease: Current Issues. London: Martin Dunitz; 2000: 173\u2013182."},{"key":"e_1_3_2_14_2","first-page":"223","volume":"7","year":"2000","unstructured":"Holme I. Lipid lowering in the patient at risk: the next decade of discovery. Br J Cardiol. 2000; 7: 223\u2013230.","journal-title":"Br J Cardiol"},{"key":"e_1_3_2_15_2","unstructured":"Randomised trial of cholesterol-lowering therapy and of antioxidant vitamins in 20 536 people at increased risk of coronary heart disease death. MRC\/BHF Heart Protection Study Collaborative Group. Circulation. 2001;104(25). Available at: http:\/\/circ.ahajournals.org\/cgi\/content\/full\/104\/25\/1B. Accessed February 11 2002."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.97.15.1440"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00522-1"},{"key":"e_1_3_2_18_2","first-page":"1895","volume":"102","year":"2000","unstructured":"Sacks FM, Tonkin AM, Shepherd J, et al. The effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation. 2000; 102: 1895\u20131900.","journal-title":"Circulation"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1984.03340270043026"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.97.15.1453"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.97.15.1446"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908053410604"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.101.5.477"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.20.1643"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/hc1002.105136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T01:34:44Z","timestamp":1715650484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/hc1002.105136"}},"subtitle":["To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels?"],"short-title":[],"issued":{"date-parts":[[2002,3,12]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,3,12]]}},"alternative-id":["10.1161\/hc1002.105136"],"URL":"https:\/\/doi.org\/10.1161\/hc1002.105136","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3,12]]},"assertion":[{"value":"2002-02-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}